ArticleJournal of translational medicine2026
FFAR4 negatively regulates colorectal cancer growth via blocking oxidative phosphorylation.
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundColorectal cancer (CRC) is closely associated with dietary factors and genetic alterations. As lipid-sensing receptors, FFARs may transduce dietary fatty acid cues into tumor-related signaling pathways. However, the role of FFAR4 in CRC remains unclear.
methodsIntegrative multi-omics approaches were used to identify FFAR4 as a key candidate within the FFAR family in CRC. FFAR4 expression and clinical relevance were evaluated using transcriptomic datasets, ROC analysis, and immunofluorescence in clinical CRC tissues. FFAR4 function was assessed by pharmacological activation with TUG891 in CRC cell lines and an MC38 syngeneic tumor model, with proliferation, cell-cycle, and metabolic assessments.
resultsFFAR4 expression was reduced in CRC tissues, and higher FFAR4 levels were associated with improved overall survival. Single-cell RNA sequencing analysis showed that FFAR4 was predominantly expressed in early differentiation states, and ROC analysis yielded an AUC > 0.8 for CRC diagnosis. TUG891-mediated FFAR4 activation inhibited CRC cell proliferation and induced cell-cycle arrest in vitro, and reduced tumor volume and tumor weight in vivo without affecting body weight. Metabolic profiling and extracellular flux analyses showed decreased mitochondrial respiration (OCR), accompanied by reduced NAD⁺ levels, a lower NAD⁺/NADH ratio, and decreased ATP/ADP, indicating altered NADH redox balance and cellular energy deficit. Consistently, aspartate was downregulated, whereas GOT1 and MDH1 were upregulated, suggesting alterations in the malate-aspartate shuttle. Meanwhile, glycolytic activity increased, as reflected by elevated ECAR and lactate levels; however, inhibition of glycolysis with 2-deoxyglucose (2-DG) did not reverse the TUG891-induced anti-proliferative effect or cell-cycle arrest, suggesting that enhanced glycolysis may represent a compensatory response.
conclusionsFFAR4 suppresses CRC growth by modulating mitochondrial function and cellular metabolism, supporting its potential as a diagnostic biomarker and therapeutic strategy for CRC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.